Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study

被引:18
作者
Alharazy, Sabah [1 ]
Kong, Norella C. T. [1 ]
Mohd, Marlyn [2 ]
Shah, Shamsul A. [3 ]
Ba'in, Arbaiyah [1 ]
Gafor, Abdul Halim Abdul [1 ]
机构
[1] Univ Kebangsaan Malaysia, Dept Med, Nephrol Unit, Med Ctr, Kuala Lumpur 56000, Malaysia
[2] Univ Kebangsaan Malaysia, Dept Med Microbiol & Immunol, Med Ctr, Kuala Lumpur 56000, Malaysia
[3] Univ Kebangsaan Malaysia, Dept Community Med, Med Ctr, Kuala Lumpur 56000, Malaysia
关键词
D O I
10.1155/2015/962046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective. This longitudinal study aimed to determine the urine monocyte chemoattractant protein-1 (uMCP-1) levels in patients with biopsy-proven lupus nephritis (LN) at various stages of renal disease activity and to compare them to current standard markers. Methods. Patients with LN-active or inactive-had their uMCP-1 levels and standard disease activity markers measured at baseline and 2 and 4 months. Urinary parameters, renal function test, serological markers, and renal SLE disease activity index-2K (renal SLEDAI-2K) were analyzed to determine their associations with uMCP-1. Results. A hundred patients completed the study. At each visit, uMCP-1 levels (pg/mg creatinine) were significantly higher in the active group especially with relapses and were significantly associated with proteinuria and renal SLEDAI-2K. Receiver operating characteristic (ROC) curves showed that uMCP-1 was a potential biomarker for LN. Whereas multiple logistic regression analysis showed that only proteinuria and serum albumin and not uMCP-1 were independent predictors of LN activity. Conclusion. uMCP-1 was increased in active LN. Although uMCP-1 was not an independent predictor for LN activity, it could serve as an adjunctive marker when the clinical diagnosis of LN especially early relapse remains uncertain. Larger and longer studies are indicated.
引用
收藏
页数:13
相关论文
共 44 条
[1]   The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis [J].
Adhya, Zoe ;
Borozdenkova, Svetlana ;
Karim, Mohammed Yousuf .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (10) :3273-3280
[2]   An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period [J].
Adler, M. ;
Chambers, S. ;
Edwards, C. ;
Neild, G. ;
Isenberg, D. .
RHEUMATOLOGY, 2006, 45 (09) :1144-1147
[3]  
Alharazy S, 2014, J CLIN CELL IMMUNOL, V5, P187, DOI 10.4172/2155-9899.1000187
[4]  
Alharazy S., 2015, THESIS
[5]   The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis [J].
Alharazy, Sabah Mohamed ;
Kong, Norella C. T. ;
Mohd, Marlyn ;
Shah, Shamsul Azhar ;
Gafor, Abdul Halim Abdul ;
Ba'in, Arbaiyah .
CLINICA CHIMICA ACTA, 2013, 425 :163-168
[6]   Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis [J].
Alzawawy, Ashraf ;
Zohary, Magdy ;
Ablordiny, Magdy ;
Eldalie, Mona .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2009, 12 (04) :311-318
[7]   Clinical presentation and monitoring of lupus nephritis [J].
Balow, JE .
LUPUS, 2005, 14 (01) :25-30
[8]  
Berthier CC, 2012, J DATA MINING GENOMI, V3
[9]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[10]  
Chaib A., 2007, ARTHRITIS RHEUMATISM, V56